Select publications

Dave SS et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351(21):2159-68. Abstract

Hainsworth JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21(9):1746-51. Abstract

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Kahl BS et al. Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study. Proc ASH 2004;Abstract 1388.

Marinus HJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-hodgkin’s lymphoma: A phase III randomized intergorup clinical trial. Proc ASH 2004;Abstract 586.

Solal-Celigny P et al. Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL): Survival analyses with a follow-up (F/Up) of at least 5 years. Proc ASH 2004;Abstract 585.

Witzig TE et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23(6):1103-8. Abstract